[1] 宋丽华,张晓一,来丽娜,等.白藜芦醇对心肌缺血再灌注过程中线粒体的保护[J].中国医院药学杂志,2015,35(10):907-911.[2] Fullmer TM,Pei S,Zhu Y,et al. Insulin suppresses ischemic preconditioning-mediatedcardioprotection through Akt-dependent mechanisms[J]. J Mol Cell Cardiol,2013,64(11):20-29.[3] 韩劲松,王辉山,韩宏光,等.心肌缺血预适应作用对老年大鼠心肌的影响及其机制的研究[J].中国循环杂志,2014,29(8):624-628.[4] 韦艳红,刘 艳,康晓新,等.依达拉奉对老年大鼠心肌缺血再灌注后线粒体功能的保护作用[J].中国老年学杂志,2015,35(15):4159-4161.[5] Yang C,Talukder MA,Varadharaj S,et al. Early ischaemic preconditioning requires Akt- and PKA-mediated activation of eNOS via serine1176 phosphorylation[J]. Cardiovasc Res,2013,97(1):33-43.[6] Rajala RV,Ranjo-Bishop M,Wang Y,et al. The p110α isoform of phosphoinositide 3-kinase is essential for cone photoreceptor survival[J]. Biochimie,2015,112(5):35-40.[7] 刘 祥,景桂霞,白 娟,等.舒芬太尼预处理对大鼠心肌缺血再灌注时PI3K/Akt的影响[J].南方医科大学学报,2014,34(3):335-340.[8] Calviño E,Estañ MC,Sánchez-Martín C,et al. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells:energy depletion,oxidative stress,and protein kinase activity modulation[J]. J Pharmacol Exp Ther,2014,348(2):324-335.[9] Peart JN,Pepe S,Reichelt ME,et al. Dysfunctional survival-signaling and stress-intolerance in aged murine and human myocardium[J]. Exp Gerontol,2014,50(2):72-81.[10] 牛宇杰,赵 炜,刘新光,等.活性氧与衰老的研究进展[J].国际老年医学杂志,2014,35(1):33-38.[11] Zuo L,Pannell BK,Re AT,et al. Po2 cycling protects diaphragm function during reoxygenation via ROS,Akt,ERK,and mitochondrial channels[J]. Am J Physiol Cell Physiol,2015,309(11):759-766.[12] Rao VK,Carlson EA,Yan SS. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration[J]. Biochim Biophys Acta,2014,1842(8):1267-1272.[13] 李 冬,史大卓,刘秀华,等.线粒体功能障碍与心肌缺血再灌注损伤[J].中华老年心脑血管病杂志,2014,16(3):318-321.[14] Taliani S,Pugliesi I,Da Settimo F. Structural requirements to obtain highly potent and selective 18 kDa translocator protein (TSPO) ligands[J]. Curr Top Med Chem,2011,11(7):860-886.[15] Javadov S,Karmazyn M,Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases[J]. J Pharmacol Exp Ther,2009,330(3):670-678. |